RespireRx Pharmaceuticals Inc.
RSPI
$0.0018
$0.0011157.14%
OTC PK
| 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | 09/30/2022 | |
|---|---|---|---|---|---|
| Net Income | 16.31% | -41.79% | 50.00% | 62.56% | 33.31% |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | 174.12% | -96.46% | -96.90% | -95.98% | -74.62% |
| Total Other Non-Cash Items | 6.67% | 80.46% | -68.29% | 2,697.06% | 73.05% |
| Change in Net Operating Assets | -51.39% | 62.63% | -34.46% | -72.01% | -18.72% |
| Cash from Operations | -44.49% | -107.42% | -26.41% | 107.20% | 37.64% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -100.00% | -32.86% | 32.73% | -81.90% | -41.02% |
| Total Debt Repaid | -- | -- | -- | -- | -858.00% |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | 98.64% |
| Cash from Financing | 42.86% | 119.74% | 32.73% | -107.10% | -13.15% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -- | 3,700.00% | 109.09% | -100.00% | 100.00% |